Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib mesylate PK in CP-CML (single and multiple dose)
CTR20170395Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by Hengrui Therapeutics. Started May 2017; status: completed.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20170395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170395.